Free Trial

Belite Bio Q4 2024 Earnings Report

Belite Bio logo
$57.02 -7.02 (-10.96%)
As of 02:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Belite Bio EPS Results

Actual EPS
-$0.32
Consensus EPS
-$0.30
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Belite Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Belite Bio Announcement Details

Quarter
Q4 2024
Time
After Market Closes

Conference Call Resources

Remove Ads

Belite Bio Earnings Headlines

Belite Bio, Inc. Appoints New Auditor
Belite Bio price target raised to $80 from $79 at Benchmark
This almost killed Elon Musk (chilling details emerge)
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.
Belite Bio's (BLTE) Buy Rating Reaffirmed at Benchmark
See More Belite Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Belite Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Belite Bio and other key companies, straight to your email.

About Belite Bio

Belite Bio (NASDAQ:BLTE), a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

View Belite Bio Profile

More Earnings Resources from MarketBeat